Pulmatrix, Inc. (PULM)

1.9600 -0.0600 (-2.97%) 收市：04:00PM EDT

Pulmatrix, Inc.

36 Crosby Drive
Suite 100
Bedford, MA 01730
United States
781 357 2333
https://www.pulmatrix.com

版塊: Healthcare
行業: Biotechnology
全職員工: 22

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Teofilo David Raad MBA	President, CEO & Director	577.72k	無	1970
Mr. Peter Ludlum CMA, MBA	Interim CFO and Principal Accounting & Financial Officer	510.22k	無	1955
Dr. Alexander M. Klibanov Ph.D.	Founder	無	無	1950

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

公司管治

截至 無 止，Pulmatrix, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。